Amendments to the Claims

Listing of Claims:

Claim 1 (canceled)

Claim 2 (currently amended): A combination~~, such as a combined preparation or a pharmaceutical composition,~~ which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and at least one compound selected from (b) a radioimmunoconjugate agent in which the active ingredients are present independently of each other in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.

Claim 3 (original): A method of treating a human suffering from tumors and who will be, is or was subject to radioimmunotherapy, which comprises administering to a said human in need of such treatment, a dose of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof, for enhancing the effect of radioimmunotherapy.

Claim 4 (currently amended): ~~Use,~~ A combination ~~or method~~ according to ~~any one of claims 1 to 3~~claim 2 wherein a daily dose of 10 to 1000 mg of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is administered to an adult human.

Claim 5 (currently amended): ~~Use,~~ A combination ~~or method~~ according to ~~any one of claims 1 to 4~~claim 2 wherein a pharmaceutically acceptable acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is administered.

Claim 6 (currently amended): ~~Use,~~ A combination ~~or method~~ according to claim 5 wherein a monomethanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is administered.

Claim 7 (currently amended): ~~Use,~~ A combination ~~or method~~ according to ~~any one of the preceding claims~~claim 2 wherein the radioimmunoconjugate is selected from the group

comprising ^{131}I-81C6, ^{131}I-MN, ^{131}I-14, ^{131}I-F6, ^{131}I-A5B7, ^{131}I-HMFG1, ^{131}I-BrE3, ^{131}I-CC49, ^{131}I-B72.3, ^{90}Y-81C6, ^{90}Y-MN, ^{90}Y-14, ^{90}Y-F6, ^{90}Y-A5B7, ^{90}Y-HMFG1, ^{90}Y-BrE3, ^{90}Y-CC49 and ^{90}Y-B72.3.

Claim 8 (currently amended): ~~Use,~~ A combination ~~or method~~ according to claim 7 wherein the radioimmunoconjugate is selected from the group consisting of ^{131}I-CC49 and ^{131}I-B72.3.

Claim 9 (currently amended): ~~Use,~~ A combination ~~or method~~ according to ~~any one of the preceding claims~~claim 2 wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is administered within a time period of 12 days before to 12 days after radioimmunotherapy.

Claim 10 (original): A method of treating a warm-blooded animal, especially a human having a tumor, comprising administering to said animal a combination, such as a combined preparation or a pharmaceutical composition, which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine, and at least one compound selected from (b) a radioimmunoconjugate agent in which the active ingredients are present independently of each other in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier.

Claim 11 (currently amended): ~~Use, or~~ A method according to ~~any one of claims 1, 3 to 8~~claim 10 for enhancing the effect of radioimmunotherapy in tumors selected from pancreatic tumors, lung cancer, breast cancer, epidermoid carcinomas, renal-cell carcinomas, neuroendocrine tumors, gynaecological cancer, urological cancer, gastrointestinal cancer, colorectal adenocarcinoma or colon cancer, pancreatic adenocarcinoma; glioblastomas, head and/or neck cancer, central nervous system cancer, bones tumors, solid pediatric tumors, haematological malignancies, AIDS-related cancer, soft-tissue sarcomas, and skin cancer.

Claim 12 (original): A kit for radioimmunotherapy, comprising:
a) a radioimmunoconjugate agent which specifically binds to a tumor-associated antigen, and
b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof.

Claim 13 (new): A method according to claim 3 wherein a daily dose of 10 to 1000 mg of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is administered to an adult human.

Claim 14 (new): A method according to claim 3 wherein a pharmaceutically acceptable acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide of the formula I is administered.

Claim 15 (new): A method according to claim 3 wherein a monomethanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is administered.

Claim 16 (new): A method according to claim 3 wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is administered within a time period of 12 days before to 12 days after radioimmunotherapy.

Claim 17 (new): A method according to claim 3 for enhancing the effect of radioimmunotherapy in tumors selected from pancreatic tumors, lung cancer, breast cancer, epidermoid carcinomas, renal-cell carcinomas, neuroendocrine tumors, gynaecological cancer, urological cancer, gastrointestinal cancer, colorectal adenocarcinoma or colon cancer, pancreatic adenocarcinoma; glioblastomas, head and/or neck cancer, central nervous system cancer, bones tumors, solid pediatric tumors, haematological malignancies, AIDS-related cancer, soft-tissue sarcomas, and skin cancer.